The protein immunoblot technique was used to identify Epstein-Barr virus-specific antigens present in sodium butyrate-induced P3HR-1 cells. Using sera from patients with either nasopharyngeal carcinoma or arthritis, 16 polypeptides were detected ranging in molecular weight from 22K to 140K. Each of the anti-EA-, anti-VCA-positive sera were found to contain antibodies to different subsets of the antigens. A 72K protein was identified which was consistent with the nuclear antigen (EBNA), and culturing cells in the presence of disodium phosphonoacetate allowed identification of 140K and 22K antigens as late viral products. Treatment of cells with sodium butyrate revealed that expression of some antigens increased in parallel with the time of incubation of the cells in butyrate while other antigens either appeared early and then decreased in intensity or were only present after a number of days of butyrate treatment. One of the antigens which decreased with the time cells were treated with butyrate was EBNA.
BaylissG. J.,
WolfH.1981; The regulated expression of Epstein-Barr virus. III. Proteins specified by EBV during the lytic cycle. Journal of General Virology 56:105–118
BaylissG. J.,
DebyG.,
WolfH.1983; An immunoprecipitation blocking assay for the analysis of EBV-induced antigens. Journal of Virological Methods 7:229–239
BoguszakováL.,
HirschL. B.,
řicháčekB.,
VonkaV.1983; Relationship between Epstein-Barr virus nuclear antigen and DNA genome number in superinfected and induced lymphoblastoid cell lines. Journal of General Virology 64:887–894
BurnetteW. N.1981; ‘‘Western Blotting”: electrophoretic transfer of proteins from SDS–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated Protein A. Analytical Biochemistry 112:195–203
CohenL. K.,
SpeckS. H.,
RobertsB. E.,
StromingerJ. L.1984; Identification and mapping of polypeptides encoded by the P3HR-1 strain of Epstein-Barr virus. Proceedings of the National Academy of Sciences, U. S. A 81:4183–4187
EdsonC. M.,
CohenL. K.,
HenleW.,
StromingerJ. L.1983; An unusually high-titer human anti-Epstein-Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesised in vitro and in vivo
. Journal of Immunology 130:919–924
EpsteinA. L.1984; Immunobiochemical characterisation with monoclonal antibodies of Epstein–Barr virus-associated early antigens in chemically induced cells. Journal of Virology 50:372–379
HamparB.,
DergeJ. G.,
MartosL. M.,
TagametsM. A.,
ChangS. Y.,
ChakrabartyM.1973; Identification of a critical period during the S-phase for activation of the Epstein–Barr virus by 5-iododeoxyuridine. Nature, London 224:214–217
HenleG.,
HenleW.,
KleinG.1971; Demonstration of two distinct components in the early antigen complex of Epstein–Barr virus-infected cells. International Journal of Cancer 8:272–278
KallinB.,
LukaJ.,
KleinG.1979; Immunochemical characterisation of Epstein–Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. Journal of Virology 32:710–726
KawanashiM.,
SugawaraK.,
ItoY.1981; Epstein-Barr virus-induced polypeptides: a comparative study with superinfected Raji, IUdR-treated and n-butyrate-treated P3HR-1 cells. Virology 109:72–81
KishishitaM.,
LukaJ.,
VrominB.,
PudusloJ. F.,
PearsonG. R.1984; Production of monoclonal antibody to a late intracellular Epstein–Barr virus-induced antigen. Virology 133:363–375
KleinG.,
DombosL.1973; Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genomes. International Journal of Cancer 11:327–337
MossD. J.,
ChanS. H.,
BurrowsS. R.,
ChewT. S.,
KaneR. G.,
StaplesJ. A.,
KunaratnamN.1983a; Epstein–Barr virus specific T-cell response in nasopharyngeal carcinoma patients. International Journal of Cancer 32:301–305
MossD. J.,
KlestovA.,
BurrowsS.,
KaneR. G.1983b; A comparison of Epstein-Barr virus-specific T-cell immunity in rheumatoid arthritis and osteoarthritis patients. Australian Journal of Experimental Biology and Medical Science 61:509–516
Mueller-LantzschN.,
YamamotoN.,
Zur HausenH.1979; Analysis of early and late Epstein-Barr virus-associated polypeptides by immunoprecipitation. Virology 97:378–387
PearsonG. R.,
VromanB.,
ChaseB.,
SculleyT.,
HummelM.,
KieffE.1983; Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. Journal of Virology 47:193–201
QualtiereL. F.,
ChaseR.,
VromanB.,
PearsonG. R.1982; Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Proceedings of the National Academy of Sciences, U. S. A 79:616–620
ReedmanT. B. M.,
KleinG.1973; Cellular localisation of an Epstein–Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. International Journal of Cancer 2:499–520
SculleyT. B.,
SpelsbergT. C.,
PearsonG. R.1984a; Characterisation of Epstein-Barr virus nuclear antigen(s) in different cell lines by radioimmunoelectrophoresis. Intervirology 22:191–200
SculleyT. B.,
WalkerP. J.,
MossD. I.,
PopeJ. H.1984b; Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis. Journal of Virology 52:88–93
StrnadB. C.,
SchusterT. C.,
HopkinsR. F.Ill,
NeubauerR. H.,
RabinH.1981; Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis. Journal of Virology 38:996–1004
TakedaK.,
FujiwaraS.,
YanoS.,
OsatoT.1983; Monoclonal antibody specific for capsid antigen of Epstein–Barr virus. Medical Microbiology and Immunology 171:225–231
Thorley-LawsonD. A.,
EdsonC. M.,
GeilingerK.1982; Epstein–Barr virus antigens – a challenge to modern biochemistry. Advances in Cancer Research 36:295–348